TP53 and non-small cell lung carcinoma: Later, Hu et al., 2018 compared TP53 mutation status in cfDNA, tissue and PBMCs from NSCLC patients and found that 42.4% (14/33) of variants were detected at both cfDNA and tissue, suggesting tumor-derived variants.